Medical News
Risk Factors for BSI in Patients with Severe ARDS Supported...
BMC Pulm Dis.
The incidence of bloodstream infection (BSI) in patients with severe ARDS supported by VV–ECMO was 22%. G– bacilli...
29 Sep 2022
Poor Timing and Failure of Source Control are Risk Factors f...
Intensive Care Med.
‘Urgent’ and successful source control was associated with improved odds of survival. Appropriateness of empirical...
26 Sep 2022
Factors Associated with The Decision to Administer Β-Lactams...
Int J Infect Dis.
Prolonged infusion (PI) for administering β-lactams was not a commonly applied strategy in sepsis and was more...
23 Sep 2022
Cystatin C and Derived Measures of Renal Function as Risk Fa...
J Crit Care.
Cystatin C and derived measures of kidney function at ICU admission are associated with an increased 90-day...
15 Sep 2022
eCMEs
Key Trials
Treatment with Casirivimab and Imdevimab Lowers Hospitalization Rates in High Risk Patients with Mild-to-Moderate COVID-19
The results of this real-world study demonstrated that treatment with casirivimab-imdevimab significantly lowered the rate of hospitalization among...
Casirivimab and Imdevimab Antibody Cocktail Clinically Beneficial in High Risk COVID-19 Patients
Casirivimab and Imdevimab antibody cocktail resulted in lesser requirement of mechanical ventilation and high-flow oxygen with no deaths as compared...
RECOVERY Trial: Efficacy and Safety of Casirivimab and Imdevimab Combination in Hospitalized COVID-19 Patients
RECOVERY Trial evaluated efficacy and safety of casirivimab and imdevimab combination in hospitalized COVID-19 patients. The study showed that in...
REGEN-COV Reduces Risk of Hospitalization and Shortens Time to Resolution of Symptoms in Symptomatic COVID-19 Patients
As per the results of this phase 3, administration of REGEN-COV decreased the risk of Covid-19–related hospitalization or death from any cause....
Slide Library
Cefuroxime (Novacef)
Cefuroxime is a second-generation cephalosporin antibiotic. It is a broad-spectrum antibacterial agent with a favorable pharmacokinetic profile....
Management of Mucormycosis in ENT Practice
Mucormycosis are the group of invasive infection caused by filamentous fungi of the Mucoraceae family. This slide set enumerates prevalence,...
Antifungal Therapy in Immunocompromised Patients
Early initiation of antifungal therapy is a major contributor to enhanced survival rate. This set of slides highlights incidence and risk factors of...
Disseminated Tuberculosis with ARDS
Disseminated TB results from widespread blood borne dissemination of TB bacilli. This presentation includes causes and risk factors of disseminated...
Our Publications
Barijak (Barictinib) Monograph
Barictinib can be useful addition for treatment of Moderate to Severe Covid 19 patients in combination with Remdesivir. Barcitinib inhibits the...
Cipmolnu (Molnupiravir) Monograph
This monograph overviews in-vitro/clinical evidence for Molnupiravir efficacy, safety and positioning.
Molnupiravir: Fact Sheet for Healthcare Givers and Recipients
This fact sheet contains the factual details about the drug molnupiravir, its restricted use under emergency situation, dosage, side effects etc....
Molnupiravir - FAQ Booklet
This document addresses frequently asked questions related to oral antiviral drug Molnupiravir in the treatment of Covid-19.
Poll
Do you perceive any clinical benefits of neurotrophic agent in the management of acute brain injury?
Yes
Sometimes
No
Total votes: 13